AI assistant
SCI Annual Report 2014
52383_rns_2014-04-25_b32969bb-b708-4eb9-9e52-784e0cff9476.pdf
Annual Report
Open in viewerOpens in your device viewer
SCI PHARMTECH, ING.
簡報
procedure ThainForm Forwardtccion begin
AX-HescoryList.Count > 0 then Foregricket ton, Inshied to History
KathardAckier, Enabled is Jalos, nnd F
CARG LIGHT GAT I TODOL WITH COLOR BOBLESCHE FINSENT TERRITORIE ONE COLOR coast plima Ibaspatch, var 1911 Reading at OldeVariable r-war-
BALLE HIFTOLYLIST COURT BAY ListoryList Delate (History) HistoryZndas in RistoryLiet.Add
AG
RiccomyTodes := HewIndex; AX Up-Seven Coable Aduce hegin Der returne in Zalis Melo today of a District case Moderate AE Tuillyden - - Likes
UP J. Items, Insert (0, UPM
olas |
員工數Employee:205 設立日期:中華民國七十六年九月十八日 Date of establishment: Sep. 18, 1987 資本額Capital:新台幣662佰萬元(NTD 662mn) 營業項目Business: 原料藥API(40.96%) 中間體Intermediate(46.82%) 特用化學品 Custom-made chemicals(12.22%)
公司概況 Outline
| Y2012 | Y2013 | |||
|---|---|---|---|---|
| 歐洲Europe | 41.74% | 36.01% | ||
| 美洲America | 22.11% | 22.80% | ||
| 亞洲Asia | 18.15% | 24.00% | ||
| 國內Taiwan | 18.00% | 17.19% | ||
| 合計Total | 100.00% | 100.00% |
Unit: K NTD
| 2013 | 2014 | |
|---|---|---|
| Jan.-Feb. | ||
| 營收Sales | 1,292,734 | 258,462 |
| 營業成本COGS | (895,753) | (159,014) |
| 毛利Gross Profit | 396,981 | 99,448 |
| 毛利率 GP Ratio | 30.7% | 38.5% |
| 營業費用Operating Expenses | (191,122) | (37,363) |
| 營業利益Operating Income | 205,859 | 62,085 |
| 營業外損益Non-Operating In/Ex | (12,079) | (783) |
| 稅前淨利 Net Profit before Tax | 193,780 | 61,302 |
| 所得稅Income Tax | (33,842) | |
| 本期淨利Net Profit after Tax | 159,938 |
產品組合-Products
| Y2011 | % | Y2012 | % | Y2013 | % | Amount |
|---|---|---|---|---|---|---|
| Di-VaNa | 24.51% | V.A. | 18.66% | PGA | 18.31% | 236,686,252 |
| PGA | 17.65% | PGA | 16.61% | Di-VaNa | 16.92% | 218,774,251 |
| V.A. | 13.76% | Di-VaNa | 15.97% | S20/38 | 8.39% | 108,535,706 |
| PPON | 10.70% | PPON | 7.88% | V.A. | 8.23% | 106,358,818 |
| M85 | 5.25% | Pent-2 | 4.78% | LPF.Na | 6.58% | 85,006,881 |
| Pent-2 | 3.73% | 5-HMT | 4.33% | PPON | 6.53% | 84,401,669 |
| DBS | 3.08% | M85 | 3.89% | 5-HMT | 4.51% | 58,335,737 |
| M115 | 2.55% | DBS | 2.73% | PEB.Na | 3.98% | 51,426,485 |
| M74 | 2.31% | M115 | 2.59% | NaVa | 3.34% | 43,215,002 |
| NBE | 1.87% | M74 | 2.18% | DBS | 2.63% | 33,956,773 |
| Total | 85.40% | Total | 79.62% | Total | 79.42% |
| No. | Product | % | Sales (NT\$) | |
|---|---|---|---|---|
| 1 | S20/38 | 20.70% | 53,490,521 | |
| $\overline{2}$ | PGA | 14.77% | 38, 162, 489 | |
| $\overline{3}$ | Di-VaNa | 7.41% | 19, 152, 944 | |
| $\overline{4}$ | DBS | 6.35% | 16,399,912 | |
| 5 | Pent-2 | 5.49% | 14,179,200 | |
| 6 | NaVa | 5.03% | 12,992,192 | |
| $\overline{7}$ | DBPR | 4.71% | 12,173,333 | |
| 8 | Chiral-auxiliary | 4.33% | 11,198,528 | |
| 9 | S-MMAA | 3.57% | 9,230,788 | |
| 10 | NBE | 3.33% | 8,596,189 |
SCI
V DEDPM_
SCI PHARMTECH, INC.
$\rightarrow VA$
NaVa
Divalproex Sodium (Di-Va)
產品介紹Product
Valproic Acid (VA)
Pyrogallolaldehyde ( PGA) - Benserazide
治療帕金森氏症之中間體 Intermediate for Parkinson's Disease
2個客戶 2 customers
Pentobarbital Sodium
Anti-inflammatory (Loxoprofen sodium) 2012年銷售5佰萬 5 mn sales in 2012. 2013年銷售85佰萬 85 mn sales in 2013 日本市場200-300公噸,200美金/公斤 Japan market:200-300MT at USD 200/kg
S20/38
5-HMT – Ritonavir,Lopinavir
- Antidepressant ( Duloxetine )
- 2013年底專利到期 Patent expired in the end of 2013 10個客戶 10 customers
- 中間體為S-MMAA(Intermediate)
- 近三年營業額約1仟萬 close to 10 mn sales over 3 years
Lorcaserin
Cyclophosphamide:高效能原料藥 Cyclophosphamide: high-potent API
GMP Status(GMP現況)
| API | CGMP certified |
CEP | DMF | MF | DMF |
|---|---|---|---|---|---|
| (TFDA) | (EDQM) | (USA) | (Japan) | (Canada) | |
| Valproic Acid (*) | 2003 | 2004 | 2003 | 2008 | 2008 |
| Allopurinol | 2004 | 2003 | 2011 | ||
| Probucol | 2004 | 2004 | |||
| Sodium Valproate | 2004 | 2006 | |||
| Divalproex Sodium (**) | 2005 | 2005 | 2010 | ||
| Bisoprolol Fumarate | 2006 | ||||
| Pentobarbital Sodium | 2009 | 2011 | |||
| Propafenone Hydrochloride | 2010 | 2012 | 2010 | 2012 | 2012 |
| Methylphenidate HCl | 2011 | ||||
| Duloxetine Hydrochloride | 2012 | 2010/2011 | |||
| Thiopental acid | 2012 | ||||
| Loxoprofen Sodium Hydrate | 2012 | 2011 | |||
| Articaine Hydrochloride | 2013 | ||||
| Clindamycin Palmitate HCl | 2011 | ||||
| Cyclophosphamide | 2012 |
